key: cord-0925844-8320aifv
authors: Nunes, Priscila Rezeck; Romao‐Veiga, Mariana; Ribeiro, Vanessa Rocha; Peracoli, Jose Carlos; Peracoli, Maria Terezinha Serrao; De Oliveira, Leandro
title: COVID‐19: A new risk factor or just a new imitator of preeclampsia? NLRP3 activation: A possible common mechanism
date: 2022-02-05
journal: J Med Virol
DOI: 10.1002/jmv.27632
sha: 97bcd39548477a859493e44032aa3eb8787c433d
doc_id: 925844
cord_uid: 8320aifv

nan

COVID-19: A new risk factor or just a new imitator of preeclampsia? NLRP3 activation: A possible common mechanism Dear Editor,

We read an article in the Journal of Medical Virology entitled "Being pregnant in the COVID-19 pandemic: Effects on the placenta in all aspects" 1 that focused on revealing the effects of the virus on the placenta in all aspects. We would like to contribute with findings regarding the interplay among inflammation caused by SARS-Cov-2 infection in placenta with Nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation, as a possible common mechanism in placenta from pregnancies complicated by preeclampsia.

It has been recognized that pregnant women constitute a special vulnerable group for complications related to the COVID-19. 2 It is possible to speculate that physiological changes observed throughout pregnancy, such as an increase in circulatory volume, pulmonary congestion, and fluctuation between Th1 and Th2 responses may contribute to the pregnancy susceptibility to respiratory virus diseases. Additionally, the COVID-19 syndrome has been associated with higher rates of adverse pregnancy outcomes such as miscarriage, preterm birth, fetal growth restriction, perinatal death, and mainly preeclampsia. 3 In fact, the intriguing pathophysiology of SARS-CoV-2 infection shares many characteristics with preeclampsia, mainly regarding the great inflammatory biomarkers release. 4 This common interface may put COVID-19 as a new imitator of preeclampsia. However, specific common immunological mechanisms between these severe diseases have not yet been described. Here, we speculate a possible common involvement of NLRP3, and consequent inflammatory cytokine storm in COVID-19 and preeclampsia. 5 Inflammasomes are activated by endogenous danger/damageassociated molecular patterns (DAMPs) and exogenous pathogen associated molecular patterns. 6 The NLRP3 inflammasome has an apoptosis-associated speck-like protein with a caspase recruitment domain (ASC), and caspase-1 as an interleukin (IL)-1β-converting enzyme. Activated caspase-1 cleaves the precursor cytokines pro-IL-1β and pro-IL-18, generating the strong inflammatory cytokines IL-1β and IL-18, respectively.

The coronavirus SARS-CoV-2 leads to direct activation of NLRP3 by a viral protein, named viroporin protein 3a. 5 This viral protein is present on the genome of SARS-CoV-2 suggesting that this virus can also directly activate NLRP3. This activation has been strongly correlated to the inflammatory response seen in some patients with COVID-19.

Preeclampsia is a placental-mediated disease. 6 9 We also demonstrated that after this initial placental NLRP3 activation, peripheral maternal innate immune cells also express NLPR3 activation, mainly among women with severe preeclampsia. 10 The clinical presentations of both COVID-19 and preeclampsia are diverse. Both diseases can lead to mild or extremely severe clinical forms, characterizing different phenotypes. van Der Berg & Velde 5 suggested that different intrinsic immune capacities can determine different degrees of NLRP3 inflammasome activation and these different responses may contribute to the diverse clinical scenarios seen in COVID-19. Similar process has been described in pregnancy once a controlled inflammation is essential for pregnancy implantation, host defense, and parturition. However, excessive inflammatory responses are correlated with several pregnancy adverse outcomes, mainly preeclampsia. 11 The role of COVID-19 as a risk factor for preeclampsia is still controversial. The main reports have pointed out that preeclampsia is associated with severe cases of COVID-19, but is not present in mild or moderate cases of the disease 12 It is important to consider that these patients with phenotypes of COVID-19 and preeclampsia

Being pregnant in the COVID-19 pandemic: effects on the placenta in all aspects

Coronavirus disease 2019 (COVID-19) pandemic and pregnancy

Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis

Pre-eclampsia-like syndrome induced by severe COVID-19: a prospective observational study

Severe COVID-19: NLRP3 inflammasome dysregulated

Pre-eclampsia

Placental syncytiotrophoblastderived extracellular vesicles carry active NEP (Neprilysin) and are increased in preeclampsia

Increased expression of NLRP3 inflammasome in placentas from pregnant women with severe preeclampsia

Hydrogen peroxide-mediated oxidative stress induces inflammasome activation in term human placental explants

Endogenous and uric acidinduced activation of NLRP3 inflammasome in pregnant women with preeclampsia

Inflammasomes: their role in normal and complicated pregnancies

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network Disease severity and perinatal outcomes of pregnant patients with coronavirus disease 2019 (COVID-19)